A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Acronyms SAKURA-2
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 25 Apr 2018 According to a Revance Therapeutics media release, data from SAKURA 1 & 2 trials will be presented at The Aesthetic Meeting 2018, organized by the American Society of Aesthetic Plastic Surgery (ASAPS).
    • 20 Feb 2018 Trial design presented at the 76th Annual Meeting of the American Academy of Dermatology
    • 01 Feb 2018 According to a Revance Therapeutics media release, data from SAKURA 1 & 2 trials will be presented at the 20th annual IMCAS (International Master Course on Aging Skin) World Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top